All News

safety data

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

Read Article
EULAR conference

CAR-T Cell Therapies in Refractory RMD

EULAR 2026 Press Release

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Read Article
RA,polyarticular,black,rheumatoid

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis

MedPage Today

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

Read Article
T2T.RA2_.jpg

Integrating D2T into T2T Practices in RA

EurekAlert!

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

Read Article
APR Safety Video Cover

Safety of Biologics and Novel Agents

Jack Cush, MD

Dr. Jack Cush reviews safety of biologics and novel agents.

Read Article
#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to patients without RA. Importantly, immune checkpoint inhibitor treatment did not appear to worsen outcomes in patients with pre-existing RA. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP087 explored cancer polygenic risk scores (PRS) in RA. RA was assoc with lower risks of breast and colorectal cancer across all PRS categories, while high prostate cancer PRS may identify RA patients with increased early prostate cancer diagnoses. @RheumNow #EULAR2026 https://t.co/WMqqSFADlW

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084 ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use. As a rheumatologist, do you vaccinate your patients? #EULAR2026 @RheumNow

sheila RHEUMarampa ( View Tweet)

RA comorbidities are changing. ILD, anxiety, depression increasing. Less extraartic. manifestations, CA & CV dz. Consider screening for cervical CA, ILD, CV dz & OP (for pts on steroids) https://t.co/WVITFXNva7 https://t.co/tggdaO9RJB

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to Professor Dennis McGonagle for being awarded the prestigious Heberden Oration Award at the 2026 British Society for Rheumatology (BSR) Conference. https://t.co/TOG5Y9tNrW https://t.co/3aumO6Z3A9

Links:

Dr. John Cush RheumNow ( View Tweet)
Integrating D2T into T2T Practices in RA Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and https://t.co/buCXeK2jNS
Dr. John Cush RheumNow ( View Tweet)
True or False: NLRP3 inflammasome activation in neutrophils triggers PAD release, increasing citrullination of intracellular proteins and contributing to rheumatoid arthritis pathogenesis. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/rVuQM3aeI2

Links:

Dr. John Cush RheumNow ( View Tweet)
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean claims data on FX in RA (2010-2017; n = 43,677). RA had more FX (aHR 1.68), regardless of b/tsDMARD use. Seropositive had more Fx (aHR 1.19), Vertebral Fx (aHR 1.4) & hip Fx (aHR 1.55) VS seronegative RA https://t.co/5Fm3o841H7 https://t.co/V0L87JYtba

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×